Health
FDA Grants Accelerated Approval to a New Treatment for Head and Neck Squamous Cell Carcinoma
Source: U.S. Food and Drug Administration (FDA)
Published:
Source summary — U.S. Food and Drug Administration (FDA)
The U.S. Food and Drug Administration today granted accelerated approval to Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for the treatment of adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed on or after platinum-based chemotherap
This page reports what the publisher stated. MYITEDU has not independently verified these claims.
Read the original article — U.S. Food and Drug Administration (FDA) ↗
Attribution: Source: U.S. Food and Drug Administration (fda.gov)
Share
Instagram does not support sharing links from websites. Download the card, post it from the Instagram app and paste the caption.
Report a correction
Tell us about an error in this item, its translation, date or attribution. Your contact details stay private and are used only to follow up.